A Study of DT2216 in Relapsed/Refractory Malignancies
Conditions: Solid Tumor; Hematologic Malignancy Intervention: Drug: DT2216 Sponsor: Dialectic Therapeutics, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials